Sublingual fentanyl citrate cost effective for cancer pain

2017 ◽  
Vol 782 (1) ◽  
pp. 29-29
Keyword(s):  
Cancer Pain ◽  
Cost Effective ◽  
Fentanyl Citrate ◽  
Sublingual Fentanyl

scholarly journals The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain

2016 ◽  
Vol 51 (3) ◽  
pp. 538-545 ◽  
Author(s):  
Andrew Davies ◽  
Gill Mundin ◽  
Joanna Vriens ◽  
Kath Webber ◽  
Alison Buchanan ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Salivary Flow ◽  
Fentanyl Citrate ◽  
Flow Rates ◽  
Breakthrough Cancer Pain ◽  
Sublingual Fentanyl

A New Fast-acting Sublingual Fentanyl (Recivit®) for Treating Breakthrough Cancer Pain

2014 ◽  
Vol 10 (01) ◽  
pp. 12 ◽  
Author(s):  
Andrew Davies ◽  
Keyword(s):  
Cancer Pain ◽  
Layer Structure ◽  
Immediate Release ◽  
Absolute Bioavailability ◽  
Fentanyl Citrate ◽  
Double Blind ◽  
Breakthrough Cancer Pain ◽  
Background Pain ◽  
New Formulation ◽  
Sublingual Fentanyl

Cancer pain presents a significant clinical challenge. Even when background pain is effectively controlled, patients often experience episodes of breakthrough cancer pain (BTcP), which typically reach maximum intensity in 10 minutes and last for 60 minutes. Immediate-release opioids are often used to treat BTcP, but only produce analgesia after 20–30 minutes and their full analgesic effect after 60–90 minutes, so transmucosal formulations of fentanyl citrate have been developed that produce analgesia more rapidly. A new sublingual transmucosal formulation (the FE tablet) utilises a unique three-layer structure and is available in dosages from 67 μg to 800 μg. This review summarises available data on the new formulation. In phase I trials, it has demonstrated dose proportionality, absolute bioavailability of approximately 70 % and higher plasma fentanyl concentrations than an oral transmucosal fentanyl citrate lozenge. In a prospective, randomised, double-blind, crossover study to evaluate efficacy and safety, pain relief was recorded from 6 minutes after administration onwards and lasted for up to 60 minutes.

A study of the use of a transdermal fentanyl patch in cats

1996 ◽  
Vol 32 (1) ◽  
pp. 19-24 ◽  
Author(s):  
M Scherk-Nixon
Keyword(s):  
Pain Control ◽  
Cost Effective ◽  
Therapeutic System ◽  
Fentanyl Patch ◽  
Postoperative Pain Control ◽  
Transdermal Fentanyl ◽  
Fentanyl Citrate ◽  
Blood Samples ◽  
Continuous Delivery ◽  
Transdermal Fentanyl Patch

A transdermal therapeutic system (TTS) has been developed for the continuous delivery of fentanyl citrate to provide ongoing analgesia in human patients with chronic pain. Several researchers believe that fentanyl transdermal patches have a place in postoperative pain control. The purpose of this study was to determine whether transdermal technology is an effective way of administering fentanyl to feline patients. Fentanyl patches were applied to the skin of six cats, and blood samples for fentanyl analysis were collected over 104 hours. This study establishes that the transdermal patch technology is an effective, long-lasting, cost-effective, noninvasive, and well-tolerated mode of deliverying fentanyl to cats.

Influence of Age on the Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Fentanyl Citrate

2004 ◽  
Vol 101 (3) ◽  
pp. 738-743 ◽  
Author(s):  
Evan D. Kharasch ◽  
Christine Hoffer ◽  
Dale Whittington
Keyword(s):  
Cancer Pain ◽  
Pupil Diameter ◽  
The Elderly ◽  
Pharmacokinetic Parameters ◽  
Clinical Effects ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Fentanyl Citrate ◽  
Oral Transmucosal Fentanyl Citrate ◽  
Older Volunteers ◽  
Older Subjects

Background Cancer pain is primarily a problem of older persons. Oral transmucosal fentanyl citrate (OTF) was developed to provide rapid analgesia and is the first drug specifically approved for treating breakthrough cancer pain. Fentanyl in OTF is absorbed across the oral mucosa but a considerable portion is swallowed and absorbed enterally. The effects of age on OTF pharmacokinetics and pharmacodynamics are unknown. This investigation evaluated OTF disposition and clinical effects in older (60-75 yr) compared with younger (18-40 yr) volunteers. Methods Healthy young (26 +/- 6 yr) and older (67 +/- 6 yr) volunteers (n = 12 each) were studied in an Institutional Review Board approved protocol. They received OTF (10 microg/kg). Plasma fentanyl and norfentanyl concentrations were determined by mass spectrometry. Fentanyl effects were measured by dark-adapted pupil diameter and by subjective self-assessments using visual analog scales. Results Plasma fentanyl and norfentanyl concentrations and pharmacokinetic parameters did not differ between younger and older subjects. Maximum pupil diameter change from baseline was significantly less in older (3.1 +/- 0.7 mm) compared with younger (4.5 +/- 1.1 mm) subjects (P < 0.05). OTF-dependent subjective assessments of alertness/sedation, energy level, confusion, clumsiness, anxiety, and nausea did not differ in the older subjects. Discussion The pharmacokinetics of OTF were not altered in older volunteers. In contrast, there was a somewhat diminished response to the miotic effects of fentanyl in older subjects. No change in OTF dosing in the elderly would appear necessary because of altered pharmacokinetics. If the response to OTF in older patients is similar to that in older volunteers and miosis is representative of analgesia and respiratory depression, then changes in OTF dosing with age alone do not appear indicated.

Sign in / Sign up

Export Citation Format

Share Document